Ginkgo Bioworks Holdings (DNA) Receivables (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Receivables data on file, last reported at $11.9 million in Q1 2026.

• Quarterly Receivables fell 54.92% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (down 54.92% YoY) and the FY2025 annual result came in at $38.5 million, up 224.13% from the prior year.
• Receivables fell to $11.9 million in Q1 2026, from $38.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $178.1 million in Q2 2022 to a low of $899000.0 in Q2 2023.
• A 5-year average of $45.1 million and a median of $24.2 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables slumped 99.5% — and 2024, when it surged 1134.93%.
• Tracing DNA's Receivables over 5 years: stood at $1.6 million in 2022, then surged by 595.89% to $10.8 million in 2023, then climbed by 9.63% to $11.9 million in 2024, then jumped by 224.13% to $38.5 million in 2025, then tumbled by 69.23% to $11.9 million in 2026.
• The last three Receivables figures came in at $11.9 million (Q1 2026), $38.5 million (Q4 2025), and $32.6 million (Q3 2025), per Business Quant data.